Rheumatoid arthritis pharmacogenomics

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 617-619

  Marsal, Sara ^a   Juliá, Antonio ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Anti TNF therapy; Genomics; Methotrexate; Microarrays; Response predictor; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME METABOLISM; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MOLECULAR DYNAMICS; NOTE; PHARMACOGENOMICS; PROMOTER REGION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; PHARMACOGENETICS;

EID: 77951581157     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.53     Document Type: Note

References (14)

1. Arnett FC, Edworthy SM, Bloch DA et al.: The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum. 31(3), 315-324 (1988).
2. Ranganathan P: An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 9(4), 439-451 (2008).
3. O'Dell JR: Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350(25), 2591-2602 (2004).
4. Fisher MC, Cronstein BN: Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 36(3), 539-545 (2009).
5. Plenge RM, Criswell LA: Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr. Opin. Rheumatol. 20(2), 145-152 (2008).
6. Klareskog L, Catrina AI, Paget S: Rheumatoid arthritis. Lancet 373(9664), 659-672 (2009).
7. Coenen MJ, Toonen EJ, Scheffer H et al.: Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8(7), 761-773 (2007).
8. Bansard C, Lequerré T, Daveau M et al.: Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford) 48(9), 1021-1028 (2009).
9. van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL: Discovery of distinctive gene expression profles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun. 4(3), 187-196 (2003).
10. Lequerré T, Gauthier-Jauneau AC, Bansard C: Gene profling in white blood cells predicts infiximab responsiveness in rheumatoid arthritis. Arthritis Res. Ther. 8(4), R105 (2006).
11. Julià A, Erra A, Palacio C et al.: An eight-gene blood expression profle predicts the response to infiximab in rheumatoid arthritis. PLoS One 4(10), E7556 (2009).
12. Julià A, Barceló M, Erra A, Palacio C, Marsal S: Identifcation of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profling in blood cells. Pharmacogenomics 10(10), 1697-1708 (2009).
13. Gurwitz D, Fortier I, Lunshof JE, Knoppers BM: Research ethics. Children and population biobanks. Science 325(5942), 818-819 (2009).
14. Frueh F W, Gurwitz D: From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5(5), 571-579 (2004).